Abstract
The diagnosis of familial non-syndromic clear cell renal cell carcinoma is one of exclusion. In families presenting with clear cell RCC a germline VHL mutation and a consitutional translocation of chromosome 3 must be excluded before familial non-syndromic clear cell RCC can be diagnosed. Large familial non-syndromic clear cell RCC kindreds are uncommon and a predisposing gene has not been identified. However inheritance is autosomal dominant in most cases and age at onset is earlier than in sporadic cases. Recognition and appropriate screening of familial non-syndromic clear cell RCC cases will reduce morbidity and mortality. Large scale collaborative linkage studies may provide a basis for the identification of familial non-syndromic clear cell RCC susceptibility gene(s).
Keywords: renal cell carcinoma, von hippel-lindau(vhl) disease, chromosome, vhl gene mutation, molecular genetic
Current Molecular Medicine
Title: Familial Non-Syndromic Clear Cell Renal Cell Carcinoma
Volume: 4 Issue: 8
Author(s): Emma R. Woodward
Affiliation:
Keywords: renal cell carcinoma, von hippel-lindau(vhl) disease, chromosome, vhl gene mutation, molecular genetic
Abstract: The diagnosis of familial non-syndromic clear cell renal cell carcinoma is one of exclusion. In families presenting with clear cell RCC a germline VHL mutation and a consitutional translocation of chromosome 3 must be excluded before familial non-syndromic clear cell RCC can be diagnosed. Large familial non-syndromic clear cell RCC kindreds are uncommon and a predisposing gene has not been identified. However inheritance is autosomal dominant in most cases and age at onset is earlier than in sporadic cases. Recognition and appropriate screening of familial non-syndromic clear cell RCC cases will reduce morbidity and mortality. Large scale collaborative linkage studies may provide a basis for the identification of familial non-syndromic clear cell RCC susceptibility gene(s).
Export Options
About this article
Cite this article as:
Woodward R. Emma, Familial Non-Syndromic Clear Cell Renal Cell Carcinoma, Current Molecular Medicine 2004; 4 (8) . https://dx.doi.org/10.2174/1566524043359728
DOI https://dx.doi.org/10.2174/1566524043359728 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
VEGF/VEGFR2 Autocrine Signaling Stimulates Metastasis in Prostate Cancer Cells
Current Angiogenesis (Discontinued) Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Myeloid Derived Suppressor Cells and Their Role in Diseases
Current Medicinal Chemistry Plant-based Adjuvant in Vaccine Immunogenicity: A Review
Current Traditional Medicine Biological Function and Medicinal Research Significance of G-Quadruplex Interactive Proteins
Current Topics in Medicinal Chemistry Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Modulation of Cellular Response to Anticancer Treatment by Caffeine: Inhibition of Cell Cycle Checkpoints, DNA Repair and More
Current Pharmaceutical Biotechnology Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)
Current Molecular Medicine Cardiac Toxicity of Antineoplastic Anthracyclines
Current Medicinal Chemistry - Anti-Cancer Agents In Vitro and In Vivo Experimental Model-based Approaches for Investigating Anti-inflammatory Properties of Coumarins
Current Medicinal Chemistry The Discovery of the Potent and Selective Antitumour Agent 2-(4-Amino-3-methylphenyl)benzothiazole (DF 203) and Related Compounds
Current Medicinal Chemistry Ethnomedicinal Uses, Phytochemistry and Pharmacology of Carica papaya Plant: A Compendious Review
Mini-Reviews in Organic Chemistry Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Review of Dose-intense Platinum and/or Paclitaxel Containing Chemotherapy in Advanced and Recurrent Epithelial Ovarian Cancer
Current Pharmaceutical Design Bench to Bedside Targeting of FLT3 in Acute Leukemia
Current Drug Targets The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology